History 0 7 0 7 O
of 8 10 8 10 O
hypersensitivity 11 27 11 27 O
reactions 28 37 28 37 O
to 38 40 38 40 O
other 41 46 41 46 O
EGFR 47 51 47 51 B-allergy_name
inhibitors 52 62 52 62 I-allergy_name

Less 0 4 63 67 O
than 5 9 68 72 O
6 10 11 73 74 B-upper_bound
months 12 18 75 81 I-upper_bound
from 19 23 82 86 O
prior 24 29 87 92 B-treatment
Radiation 30 39 93 102 I-treatment
Therapy 40 47 103 110 I-treatment
( 48 49 111 112 O
Arm 49 52 112 115 O
1 53 54 116 117 O
) 54 55 117 118 O

Male 0 4 119 123 B-gender

Metastatic 0 10 124 134 B-cancer
disease 11 18 135 142 I-cancer

Patients 0 8 143 151 O
must 9 13 152 156 O
agree 14 19 157 162 B-contraception_consent
to 20 22 163 165 I-contraception_consent
use 23 26 166 169 I-contraception_consent
a 27 28 170 171 I-contraception_consent
medically 29 38 172 181 I-contraception_consent
effective 39 48 182 191 I-contraception_consent
method 49 55 192 198 I-contraception_consent
of 56 58 199 201 I-contraception_consent
contraception 59 72 202 215 I-contraception_consent
during 73 79 216 222 O
and 80 83 223 226 O
for 84 87 227 230 O
a 88 89 231 232 O
period 90 96 233 239 O
of 97 99 240 242 O
three 100 105 243 248 B-upper_bound
months 106 112 249 255 I-upper_bound
after 113 118 256 261 O
the 119 122 262 265 O
treatment 123 132 266 275 B-treatment
period 133 139 276 282 O
. 139 140 282 283 O
A 141 142 284 285 O
pregnancy 143 152 286 295 B-pregnancy
test 153 157 296 300 O
will 158 162 301 305 O
be 163 165 306 308 O
performed 166 175 309 318 O
on 176 178 319 321 O
each 179 183 322 326 O
premenopausal 184 197 327 340 O
female 198 204 341 347 B-gender
of 205 207 348 350 O
childbearing 208 220 351 363 O
potential 221 230 364 373 O
immediately 231 242 374 385 O
prior 243 248 386 391 O
to 249 251 392 394 O
entry 252 257 395 400 O
into 258 262 401 405 O
the 263 266 406 409 O
research 267 275 410 418 O
study 276 281 419 424 O

Patients 0 8 425 433 O
must 9 13 434 438 O
have 14 18 439 443 O
a 19 20 444 445 O
Karnofsky 21 30 446 455 B-clinical_variable
performance 31 42 456 467 I-clinical_variable
status 43 49 468 474 I-clinical_variable
≥70 50 53 475 478 O
% 53 54 478 479 I-lower_bound
( 55 56 480 481 O
or 56 58 481 483 O
the 59 62 484 487 O
equivalent 63 73 488 498 O
ECOG 74 78 499 503 B-clinical_variable
level 79 84 504 509 I-clinical_variable
of 85 87 510 512 O
0 88 89 513 514 O
- 89 90 514 515 O
2 90 91 515 516 B-upper_bound
) 91 92 516 517 O
( 93 94 518 519 O
see 94 97 519 522 O
Appendix 98 106 523 531 O
Performance 107 118 532 543 O
Status 119 125 544 550 O
Evaluation 126 136 551 561 O
) 136 137 561 562 O
and 138 141 563 566 O
an 142 144 567 569 O
expected 145 153 570 578 B-clinical_variable
survival 154 162 579 587 I-clinical_variable
of 163 165 588 590 O
≥ 166 167 591 592 O
three 168 173 593 598 B-lower_bound
months 174 180 599 605 I-lower_bound

Patients 0 8 606 614 O
must 9 13 615 619 O
have 14 18 620 624 O
adequate 19 27 625 633 O
hematologic 28 39 634 645 O
reserve 40 47 646 653 O
with 48 52 654 658 O
WBC≥3000 53 61 659 667 B-clinical_variable
/ 61 62 667 668 I-lower_bound
mm3 62 65 668 671 I-lower_bound
, 65 66 671 672 O
absolute 67 75 673 681 B-clinical_variable
neutrophils 76 87 682 693 I-clinical_variable
≥1500 88 93 694 699 O
/ 93 94 699 700 I-lower_bound
mm3 94 97 700 703 I-lower_bound
and 98 101 704 707 O
platelets 102 111 708 717 B-clinical_variable
≥100,000/ 112 121 718 727 O
mm3 122 125 728 731 I-lower_bound
. 125 126 731 732 O
Patients 127 135 733 741 O
who 136 139 742 745 O
are 140 143 746 749 O
on 144 146 750 752 O
Coumadin 147 155 753 761 O
must 156 160 762 766 O
have 161 165 767 771 O
a 166 167 772 773 O
platelet 168 176 774 782 B-clinical_variable
count 177 182 783 788 I-clinical_variable
of 183 185 789 791 O
≥150,000/ 186 195 792 801 O
mm3 196 199 802 805 I-lower_bound

Patients 0 8 806 814 O
must 9 13 815 819 O
have 14 18 820 824 O
at 19 21 825 827 O
least 22 27 828 833 O
one 28 31 834 837 B-lower_bound
confirmed 32 41 838 847 O
and 42 45 848 851 O
evaluable 46 55 852 861 O
tumor 56 61 862 867 B-cancer
site 62 66 868 872 O
. 66 67 872 873 O
* 67 68 873 874 O
The 69 72 875 878 O
recurrence 73 83 879 889 O
must 84 88 890 894 O
have 89 93 895 899 O
bidimensional 94 107 900 913 O
measurements 108 120 914 926 O
by 121 123 927 929 O
clinical 124 132 930 938 O
examination 133 144 939 950 O
or 145 147 951 953 O
CT 148 150 954 956 B-treatment
/ 150 151 956 957 O
MRI 151 154 957 960 B-treatment
/ 154 155 960 961 O
PET 155 158 961 964 B-treatment
scan 159 163 965 969 I-treatment
. 163 164 969 970 O
A 165 166 971 972 O
confirmed 167 176 973 982 O
recurrence 177 187 983 993 O
site 188 192 994 998 O
may 193 196 999 1002 O
also 197 201 1003 1007 O
be 202 204 1008 1010 O
biopsy 205 211 1011 1017 O
- 211 212 1017 1018 O
proven 212 218 1018 1024 O

Patients 0 8 1025 1033 O
who 9 12 1034 1037 O
refuse 13 19 1038 1044 O
surgery 20 27 1045 1052 B-treatment

Patients 0 8 1053 1061 O
with 9 13 1062 1066 O
a 14 15 1067 1068 O
documented 16 26 1069 1079 O
diagnosis 27 36 1080 1089 O
of 37 39 1090 1092 O
recurrent 40 49 1093 1102 O
head 50 54 1103 1107 B-cancer
and 55 58 1108 1111 I-cancer
neck 59 63 1112 1116 I-cancer
squamous 64 72 1117 1125 I-cancer
cell 73 77 1126 1130 I-cancer
cancer 78 84 1131 1137 I-cancer
( 85 86 1138 1139 O
squamous 86 94 1139 1147 B-cancer
cell 95 99 1148 1152 I-cancer
carcinoma 100 109 1153 1162 I-cancer
, 109 110 1162 1163 O
including 111 120 1164 1173 O
nasopharyngeal 121 135 1174 1188 B-cancer
cancer 136 142 1189 1195 I-cancer
, 142 143 1195 1196 O
or 144 146 1197 1199 O
adenoid 147 154 1200 1207 B-cancer
cystic 155 161 1208 1214 I-cancer
carcinoma 162 171 1215 1224 I-cancer
) 171 172 1224 1225 O

Patients 0 8 1226 1234 O
with 9 13 1235 1239 O
significant 14 25 1240 1251 O
intercurrent 26 38 1252 1264 O
medical 39 46 1265 1272 B-chronic_disease
or 47 49 1273 1275 O
psychiatric 50 61 1276 1287 B-chronic_disease
conditions 62 72 1288 1298 I-chronic_disease
that 73 77 1299 1303 O
would 78 83 1304 1309 O
place 84 89 1310 1315 O
them 90 94 1316 1320 O
at 95 97 1321 1323 O
increased 98 107 1324 1333 O
risk 108 112 1334 1338 O
or 113 115 1339 1341 O
affect 116 122 1342 1348 O
their 123 128 1349 1354 O
ability 129 136 1355 1362 O
to 137 139 1363 1365 O
receive 140 147 1366 1373 O
or 148 150 1374 1376 O
comply 151 157 1377 1383 O
with 158 162 1384 1388 O
treatment 163 172 1389 1398 B-treatment
or 173 175 1399 1401 O
post 176 180 1402 1406 B-treatment
- 180 181 1406 1407 I-treatment
treatment 181 190 1407 1416 I-treatment
clinical 191 199 1417 1425 O
monitoring 200 210 1426 1436 O

Pre 0 3 1437 1440 O
- 3 4 1440 1441 O
enrollment 4 14 1441 1451 O
chemistry 15 24 1452 1461 O
parameters 25 35 1462 1472 O
must 36 40 1473 1477 O
show 41 45 1478 1482 O
: 45 46 1482 1483 O
bilirubin<1.5X 47 61 1484 1498 B-clinical_variable
the 62 65 1499 1502 I-upper_bound
institutional 66 79 1503 1516 I-upper_bound
upper 80 85 1517 1522 I-upper_bound
limit 86 91 1523 1528 I-upper_bound
of 92 94 1529 1531 I-upper_bound
normal 95 101 1532 1538 I-upper_bound
( 102 103 1539 1540 I-upper_bound
IUNL 103 107 1540 1544 I-upper_bound
) 107 108 1544 1545 I-upper_bound
; 108 109 1545 1546 O
AST 110 113 1547 1550 B-clinical_variable
or 114 116 1551 1553 O
ALT<2.5X 117 125 1554 1562 B-clinical_variable
IUNL 126 130 1563 1567 I-upper_bound
and 131 134 1568 1571 O
creatinine<1.5X 135 150 1572 1587 B-clinical_variable
IUNL 151 155 1588 1592 I-upper_bound

Pre 0 3 1593 1596 B-clinical_variable
- 3 4 1596 1597 I-clinical_variable
enrollment 4 14 1597 1607 I-clinical_variable
coagulation 15 26 1608 1619 I-clinical_variable
parameters 27 37 1620 1630 I-clinical_variable
( 38 39 1631 1632 I-clinical_variable
PT 39 41 1632 1634 I-clinical_variable
and 42 45 1635 1638 I-clinical_variable
PTT 46 49 1639 1642 I-clinical_variable
) 49 50 1642 1643 I-clinical_variable
must 51 55 1644 1648 O
be 56 58 1649 1651 O
≤1.5X 59 64 1652 1657 O
the 65 68 1658 1661 I-upper_bound
IUNL 69 73 1662 1666 I-upper_bound

Pre 0 3 1667 1670 O
- 3 4 1670 1671 O
existing 4 12 1671 1679 O
cardiac 13 20 1680 1687 B-chronic_disease
or 21 23 1688 1690 O
respiratory 24 35 1691 1702 B-chronic_disease
disorders 36 45 1703 1712 I-chronic_disease

Previous 0 8 1713 1721 O
exposure 9 17 1722 1730 O
to 18 20 1731 1733 O
Cetuximab 21 30 1734 1743 B-treatment

Tumor 0 5 1744 1749 B-cancer
Recurrence 6 16 1750 1760 O
which 17 22 1761 1766 O
is 23 25 1767 1769 O
surgically 26 36 1770 1780 O
unresectable 37 49 1781 1793 O

Unrelated 0 9 1794 1803 O
malignancy 10 20 1804 1814 B-cancer
within 21 27 1815 1821 O
3 28 29 1822 1823 B-upper_bound
years 30 35 1824 1829 I-upper_bound

Women 0 5 1830 1835 B-gender
of 6 8 1836 1838 O
childbearing 9 21 1839 1851 O
potential 22 31 1852 1861 O

Women 0 5 1862 1867 B-gender
who 6 9 1868 1871 O
are 10 13 1872 1875 O
pregnant 14 22 1876 1884 B-pregnancy

female 0 6 1885 1891 B-gender
patients 7 15 1892 1900 I-gender

fertile 0 7 1901 1908 O
men 8 11 1909 1912 B-gender

will 0 4 1913 1917 O
be 5 7 1918 1920 O
informed 8 16 1921 1929 O
as 17 19 1930 1932 O
to 20 22 1933 1935 O
the 23 26 1936 1939 O
potential 27 36 1940 1949 O
risk 37 41 1950 1954 O
of 42 44 1955 1957 O
procreation 45 56 1958 1969 O
while 57 62 1970 1975 O
participating 63 76 1976 1989 O
in 77 79 1990 1992 O
this 80 84 1993 1997 O
research 85 93 1998 2006 O
trial 94 99 2007 2012 O
and 100 103 2013 2016 O
will 104 108 2017 2021 O
be 109 111 2022 2024 O
advised 112 119 2025 2032 O
that 120 124 2033 2037 O
they 125 129 2038 2042 O
must 130 134 2043 2047 O
use 135 138 2048 2051 B-contraception_consent
effective 139 148 2052 2061 I-contraception_consent
contraception 149 162 2062 2075 I-contraception_consent
during 163 169 2076 2082 O
and 170 173 2083 2086 O
for 174 177 2087 2090 O
a 178 179 2091 2092 O
period 180 186 2093 2099 O
of 187 189 2100 2102 O
three 190 195 2103 2108 B-upper_bound
months 196 202 2109 2115 I-upper_bound
after 203 208 2116 2121 O
the 209 212 2122 2125 O
treatment 213 222 2126 2135 B-treatment
period 223 229 2136 2142 O

≥18 0 3 2143 2146 O
years 4 9 2147 2152 I-lower_bound
of 10 12 2153 2155 O
age 13 16 2156 2159 B-age

